Journal
ONCOGENE
Volume 26, Issue 27, Pages 4032-4037Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1210170
Keywords
MEF; ELF4; RNA interference; ovarian cancer
Funding
- NCI NIH HHS [CA052477, K01 CA099156] Funding Source: Medline
- NHLBI NIH HHS [K08 HL4478] Funding Source: Medline
- NIDDK NIH HHS [R01 DK052208] Funding Source: Medline
Ask authors/readers for more resources
We have previously shown that MEF ( myeloid ELF1-like factor, also known as ELF4) functions as a transcriptional activator of the interleukin ( IL)-8, perforin, granulocyte macrophage-colonyst imulating factor ( GM-CSF) and IL-3 genes in hematopoietic cells. MEF is also expressed in non-hematopoietic tissues including certain ovarian cancer cells. To de. ne the function of MEF in these cells, we examined primary human ovarian epithelial tumors and found that MEF is expressed in a significant proportion of ovarian carcinomas, and in the CAOV3 and SKOV3 ovarian cancer cell lines, but not in normal ovarian surface epithelium. Manipulating MEF levels in these cell lines altered their behavior; reducing MEF levels, using short hairpin RNA expressing vectors, significantly inhibited the proliferation of SKOV3 and CAOV3 cells in culture, and impaired the anchorage-independent growth of CAOV3 cells. Overexpression of MEF in SKOV3 cells ( via retroviral transduction) significantly increased their growth rate, enhanced colony formation in soft agar and promoted tumor formation in nude mice. The oncogenic activity of MEF was further shown by the ability of MEF to transform NIH3T3 cells, and induce their tumor formation in nude mice. MEF is an important regulator of the tumorigenic properties of ovarian cancer cells and could be used a therapeutic target in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available